Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
19F MRI Ventilation in Healthy and CF Subjects
NCT03489590Phase 1Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Jul 2015
- Primary completion
- Dec 2018
- Modality
- GAS (Genetic analysis systems)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of perflutren in cystic fibrosis (CF), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Obtain technically sufficient 19F MRI images at 1 day. Started Jul 2015; status: completed.
02
Drugs
perflutren
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03489590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03489590.